Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 6/20 | 0.68 |
| ▸ | PLA2G5 | P39877 | 3/20 | 0.68 |
| ▸ | NOD1 | Q9Y239 | 6/20 | 0.55 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 4/20 | 0.46 |
| ▸ | CES1 | P23141 | 4/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5162305 | 1.00 | PLA2G2A (0.68) | PLA2G2APLA2G5NOD1PLA2G4ACES2 | |
| SCHEMBL28306846 | 1.00 | PLA2G2A (0.68) | PLA2G2APLA2G5NOD1PLA2G4ACES2 | |
| SCHEMBL5162407 | 1.00 | PLA2G2A (0.68) | PLA2G2APLA2G5NOD1PLA2G4ACES2 | |
| SCHEMBL5164391 | 0.94 | PLA2G2A (0.59) | PLA2G2APLA2G5NOD1PLA2G4ACES2 | |
| SCHEMBL2769449 | 0.90 | PLA2G2A (0.72) | PLA2G2APLA2G5NOD1PLA2G4ACES2 | |
| SCHEMBL2770510 | 0.90 | PLA2G2A (0.72) | PLA2G2APLA2G5NOD1PLA2G4ACES2 | |
| SCHEMBL2770844 | 0.88 | PLA2G2A (0.68) | PLA2G2APLA2G5NOD1PLA2G4A | |
| SCHEMBL2770848 | 0.88 | PLA2G2A (0.68) | PLA2G2APLA2G5NOD1PLA2G4A | |
| SCHEMBL5501051 | 0.85 | PLA2G2A (0.74) | PLA2G2APLA2G5NOD1PLA2G4ACES2 | |
| SCHEMBL5501044 | 0.85 | PLA2G2A (0.74) | PLA2G2APLA2G5NOD1PLA2G4ACES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10702497-B2 | Use of acyl-homoserine lactone derivatives as anti-thrombotic agents | THE UNIVERSITY OF TOLEDO (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190111023-A1 | USE OF ACYL-HOMOSERINE LACTONE DERIVATIVES AS ANTI-THROMBOTIC AGENTS | THE UNIVERSITY OF TOLEDO (US) | 2019-04-18 | — | — | US | disclosed |
| US-10195177-B2 | Use of acyl-homoserine lactone derivatives as anti-thrombotic agents | THE UNIVERSITY OF TOLEDO (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180280345-A1 | USE OF ACYL-HOMOSERINE LACTONE DERIVATIVES AS ANTI-THROMBOTIC AGENTS | THE UNIVERSITY OF TOLEDO (US) | 2018-10-04 | — | — | US | disclosed |
| EP-1795205-B1 | Method for accessing microbial diversity | FRAUNHOFER USA INC (US) | 2012-05-02 | — | — | EP | disclosed |
| CN-101705212-B | N-acylhomoserine lactonas, production method thereof and special recombinant bacterium | FEED RES INST CAAS | 2011-07-27 | — | — | CN | disclosed |
| US-20110124522-A1 | Methods of Disrupting Quorum Sensing to Affect Microbial Population Cell Density | ATHENA BIOTECHNOLOGIES, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110065122-A1 | METHOD FOR ACCESSING MICROBIAL DIVERSITY | FRAUNHOFER USA, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| CN-101705212-A | N-acylhomoserine lactonas, production method thereof and special recombinant bacterium | FEED RES INST CAAS | 2010-05-12 | — | — | CN | disclosed |
| EP-2076283-A2 | METHODS OF DISRUPTING QUORUM SENSING TO AFFECT MICROBIAL POPULATION CELL DENSITY | Athena Biotechnologies, Inc. (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20090130688-A1 | Method for Accessing Microbial Diversity | FRAUNHOFER USA, INC. (DE) | 2009-05-21 | — | — | US | disclosed |
| US-7494810-B2 | Method for accessing microbial diversity | FRANHOFER USA INCORPORATED (US) | 2009-02-24 | — | — | US | disclosed |
| WO-2008066631-A2 | METHODS OF DISRUPTING QUORUM SENSING TO AFFECT MICROBIAL POPULATION CELL DENSITY | ATHENA BIOTECHNOLOGIES, INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| US-20080038767-A1 | Method for accessing microbial diversity | ATHENA BIOTECHNOLOGIES, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| EP-1795205-A2 | Method for accessing microbial diversity | Fraunhofer USA, Inc. (US) | 2007-06-13 | — | — | EP | disclosed |
| EP-1476188-B1 | METHOD FOR ACCESSING MICROBIAL DIVERSITY | FRAUNHOFER USA INC (US) | 2007-04-18 | — | — | EP | disclosed |
| EP-1476188-A4 | METHOD FOR ACCESSING MICROBIAL DIVERSITY | FRAUNHOFER USA INC (US) | 2005-03-23 | — | — | EP | disclosed |
| EP-1476188-A2 | METHOD FOR ACCESSING MICROBIAL DIVERSITY | Fraunhofer USA, Inc. (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20040038374-A1 | Method for accessing microbial diversity | HERCULES INCORPORATED | 2004-02-26 | — | — | US | disclosed |
| WO-2003066880-A2 | METHOD FOR ACCESSING MICROBIAL DIVERSITY | FRAUNHOFER USA INC. (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10702497-B2 | Use of acyl-homoserine lactone derivatives as anti-thrombotic agents | SERPINC1, PLA2G7, SELP | PLA2G2A 126/4885PLA2G5 92/4885NOD1 2934/4885 |
| US-20190111023-A1 | USE OF ACYL-HOMOSERINE LACTONE DERIVATIVES AS ANTI-THROMBOTIC AGENTS | SERPINC1, PLA2G7, SELP | PLA2G2A 126/4885PLA2G5 92/4885NOD1 2934/4885 |
| US-10195177-B2 | Use of acyl-homoserine lactone derivatives as anti-thrombotic agents | SERPINC1, PLA2G7, SELP | PLA2G2A 126/4885PLA2G5 92/4885NOD1 2934/4885 |
| US-20180280345-A1 | USE OF ACYL-HOMOSERINE LACTONE DERIVATIVES AS ANTI-THROMBOTIC AGENTS | SERPINC1, PLA2G7, SELP | PLA2G2A 126/4885PLA2G5 92/4885NOD1 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.